Denmark · Delayed Price · Currency is DKK Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of DKK 94.21 billion. The enterprise value is 117.20 billion.
| Market Cap | 94.21B |
| Enterprise Value | 117.20B |
Important Dates
The next confirmed earnings date is Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | May 18, 2026 |
Share Statistics
Coloplast has 225.17 million shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 207.17M |
| Shares Outstanding | 225.17M |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.25% |
| Owned by Institutions (%) | 20.75% |
| Float | 144.57M |
Valuation Ratios
The trailing PE ratio is 34.13 and the forward PE ratio is 16.25. Coloplast's PEG ratio is 1.99.
| PE Ratio | 34.13 |
| Forward PE | 16.25 |
| PS Ratio | 3.31 |
| PB Ratio | 7.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.03 |
| P/OCF Ratio | 12.28 |
| PEG Ratio | 1.99 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.15, with an EV/FCF ratio of 18.69.
| EV / Earnings | 42.42 |
| EV / Sales | 4.12 |
| EV / EBITDA | 13.15 |
| EV / EBIT | 15.27 |
| EV / FCF | 18.69 |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 1.78.
| Current Ratio | 1.56 |
| Quick Ratio | 0.88 |
| Debt / Equity | 1.78 |
| Debt / EBITDA | 2.67 |
| Debt / FCF | 3.80 |
| Interest Coverage | 11.52 |
Financial Efficiency
Return on equity (ROE) is 18.53% and return on invested capital (ROIC) is 14.74%.
| Return on Equity (ROE) | 18.53% |
| Return on Assets (ROA) | 10.12% |
| Return on Invested Capital (ROIC) | 14.74% |
| Return on Capital Employed (ROCE) | 19.05% |
| Weighted Average Cost of Capital (WACC) | 6.25% |
| Revenue Per Employee | 1.65M |
| Profits Per Employee | 160,518 |
| Employee Count | 17,213 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 2.36 |
Taxes
In the past 12 months, Coloplast has paid 1.21 billion in taxes.
| Income Tax | 1.21B |
| Effective Tax Rate | 30.51% |
Stock Price Statistics
The stock price has decreased by -28.80% in the last 52 weeks. The beta is 0.56, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -28.80% |
| 50-Day Moving Average | 433.06 |
| 200-Day Moving Average | 456.39 |
| Relative Strength Index (RSI) | 39.25 |
| Average Volume (20 Days) | 383,031 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of DKK 28.44 billion and earned 2.76 billion in profits. Earnings per share was 12.26.
| Revenue | 28.44B |
| Gross Profit | 19.12B |
| Operating Income | 7.67B |
| Pretax Income | 3.98B |
| Net Income | 2.76B |
| EBITDA | 8.63B |
| EBIT | 7.67B |
| Earnings Per Share (EPS) | 12.26 |
Balance Sheet
The company has 817.00 million in cash and 23.80 billion in debt, with a net cash position of -22.99 billion or -102.08 per share.
| Cash & Cash Equivalents | 817.00M |
| Total Debt | 23.80B |
| Net Cash | -22.99B |
| Net Cash Per Share | -102.08 |
| Equity (Book Value) | 13.37B |
| Book Value Per Share | 59.36 |
| Working Capital | 3.74B |
Cash Flow
In the last 12 months, operating cash flow was 7.67 billion and capital expenditures -1.40 billion, giving a free cash flow of 6.27 billion.
| Operating Cash Flow | 7.67B |
| Capital Expenditures | -1.40B |
| Depreciation & Amortization | 951.00M |
| Net Borrowing | -717.00M |
| Free Cash Flow | 6.27B |
| FCF Per Share | 27.85 |
Margins
Gross margin is 67.23%, with operating and profit margins of 26.98% and 9.71%.
| Gross Margin | 67.23% |
| Operating Margin | 26.98% |
| Pretax Margin | 13.98% |
| Profit Margin | 9.71% |
| EBITDA Margin | 30.32% |
| EBIT Margin | 26.98% |
| FCF Margin | 22.04% |
Dividends & Yields
This stock pays an annual dividend of 23.00, which amounts to a dividend yield of 5.50%.
| Dividend Per Share | 23.00 |
| Dividend Yield | 5.50% |
| Dividend Growth (YoY) | 4.55% |
| Years of Dividend Growth | 17 |
| Payout Ratio | 187.59% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 5.58% |
| Earnings Yield | 2.93% |
| FCF Yield | 6.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Coloplast is 468.29, which is 11.92% higher than the current price. The consensus rating is "Hold".
| Price Target | 468.29 |
| Price Target Difference | 11.92% |
| Analyst Consensus | Hold |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 5.51% |
| EPS Growth Forecast (3Y) | 16.53% |
Stock Splits
The last stock split was on December 19, 2012. It was a forward split with a ratio of 5.
| Last Split Date | Dec 19, 2012 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Coloplast has an Altman Z-Score of 3.78 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.78 |
| Piotroski F-Score | 6 |